ITEM 8: In line with the modified AFEP/MEDEF corporate governance code as revised
in June 2018, the company proposes to add a CSR criterion to the annual bonus. We
regret that the company does not indicate which CSR indicator will be implemented and
whether it will be quantifiable or not. However, the 2019 remuneration policy is better
than the previous one, therefore we support item 8.
ITEM 10: the company’s disclosure improved compared to last year as now it disclosed
achievement rates for each of the financial criteria. However, its transparency remains
below French and European standards (for example, Novartis, one of Sanofi’s European
competitors, disclosed targets of each annual bonus criterion and achievement rates). An
improved disclosure would allow for a better understanding of amounts granted (indeed,
the 2018 bonus amounting to €1,855,800 does not seem to be sufficiently justified).
We note that Olivier Brandicourt (CEO, 63) and Serge Weinberg (Chairman, 68) will
reach the statutory age limits (respectively 65 and 70) in 2021. The company's
transparency on its succession planning in the annual report is quite appreciated.
Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Repsol, BP, Shell and Total have committed to achieving net zero by 2050. However, only the initial stages of a change in the model are currently visible. COVID-19 could be an opportunity for change. Cf. report published last evening. - ...
>Selling its stake in Regeneron - Sanofi is pressing ahead with its major moves, which we clearly welcome. After the announcement to operate its OTC franchise on a standalone basis and the spin-off of its API company in 2022, the group yesterday announced it was selling its stake in Regeneron. We are not surprised by this strategic decision which very much ties in with the group’s story. The recent rearrangements made to the agreements between the two parties and Sano...
Aucun changement au sein du Conseil d'administration n'est soumis au vote des actionnaires à cette Assemblée Générale. A l'exception des représentants de l'actionnaire de contrôle qui ne perçoivent pas de rémunération, les rémunérations des dirigeants sont bien trop généreuses par rapport à celles des dirigeants des sociétés de taille comparable pour être soutenues (résolutions 5 à 10). Les politiques de rémunération pour 2020 seront approuvées en raison d'une légère amélioration liée à la mise en place d'un critère RSE. Cependant, elles continueront de générer des montants trop importants (...
Proxinvest attire l’attention des actionnaires sur plusieurs points. Tout d’abord il est à noter le changement d’actionnariat. En effet durant l’été 2019, la société Searchlight a lancé une offre publique sur les titres de la société Latécoère. Dans ce contexte la société l’annonce du rachat de ses titres détenus par les sociétés Apollo et Monarch et de la société CVi Partners, par Searchlight Capital Partners. De ce fait, ce changement d'actionnariat a entrainé de nombreuses modifications dans la gouvernance. Le premier effet visible est le conseil d'administration qui est totalement chang...
Selectirente continue son intégration dans le réseau d’investissement de Tikehau Capital suite à l’acquisition de plus de 50% du capital par le fonds français notamment en consolidant ses positions au conseil de surveillance grâce à la nomination de Nathalie de Mortemart. Notons également la pérennité de la convention de gestion entre la société et Sofidy (détnue à 100% par Tikehau Capital) dont le coût semble particulièrement élevé (25% du chiffre d’affaires contre une moyenne sectorielle de frais de personnels de 10%). La majorité des ressources de l’augmentation de capital restant à être ...
General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company. One of the major shareholders, Roland Oetker, is the former President and since 2008 the Honorary President of DSW, the local partner of ECGS. This report has been prepared using standard ECGS guidelines. Evotec was founded 19...
In general, Danske Bank is in compliance with the Danish regulations relating to organisation and procedures of the Annual General Meeting. Under ITEM 4f it is proposed to re-appoint Ms. Carol Sergeant as Vice Chairman of the board of directors. Although she is considered independent, ECGS does NOT approve of the re-appointment of any board members who were part of the board of directors at the time of the money laundering scandal in Estonia. Accordingly, ECGS recommends to vote OPPOSE. Under ITEM 7 authorisation is sought to repurchase own shares. Although the authority requested woul...
General: The AGM is to be held in the form of a virtual AGM in accordance with the German Law to Mitigate the Consequences of the COVID-19 Pandemic. The physical presence of shareholders or their authorised proxies is not possible. The voting rights may therefore be exercised solely by postal vote or by granting authority to the proxies designated by the Company. Item 2: Management and Supervisory Board are proposing a dividend of EUR 1.10 per share (increased by 733.33% from EUR 0.15) which corresponds to a payout ratio of 53.40% per share (EPS: EUR 2.06). In view of the recent events rel...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.